Sequoia Sciences has an unparalleled collection of structurally diverse natural product compounds isolated from plants.  From this collection, Sequoia has identified compounds that may potentially provide new and alternative treatments for acute bacterial infections and chronic infections involving bacterial biofilms. Based upon these results, Sequoia Sciences is embarking on preclinical development programs with the goals of addressing the unmet medical needs for the treatment of lung infections in cystic fibrosis patients and recurrent urinary tract infections. These programs consist of small molecules targeting gram-positive and gram-negative bacterial infections and vaccines for the treatment and prevention of recurrent urinary tract infections. To this purpose, we are engaged in collaborations with other laboratories, universities, and companies.  Our goal is to improve the quality of life for those individuals significantly affected by acute bacterial infections and chronic infections involving bacterial biofilms.

Presentations | See All

Recent Publications | See All

April 2010: Williams, R.B.; Hu, J.F.; Olson, K.M.; Norman, V.L.; Goering, M.G.; O'Neil-Johnson, M.; Eldridge, G.R.; Starks, C. "Antibiotic Indole Sesquiterpene Alkaloid from Greenwayodendron suaveolens with a New Natural Product Framework" Journal of Natural Products, 2010, accepted. This publication describes a novel antibacterial with an MIC90 of 4 ug/ml against clinical isolates of MRSA.